Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction

K. Takenaka, S. Yasuda, S. Miyazaki, T. Kurita, Y. Sutani, I. Morii, S. Daikoku, S. Kamakura, H. Nonogi

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Abstract

Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive anterior infarction and severe ventricular dysfunction. The malignant ventricular tachyarrhythmia was effectively suppressed at a relatively low dose, without compromising the hemodynamics, indicating that this potent K+ channel blocker has therapeutic potential for acute myocardial infarction.

Original languageEnglish
Pages (from-to)60-62
Number of pages3
JournalJAPANESE CIRCULATION JOURNAL
Volume65
Issue number1
DOIs
Publication statusPublished - 2001
Externally publishedYes

Keywords

  • Antiarrhythmia agents
  • Electrocardiography
  • Myocardial infarction

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction'. Together they form a unique fingerprint.

Cite this